HC Wainwright Has Positive Outlook for PLX FY2026 Earnings

Protalix BioTherapeutics, Inc. (NYSE:PLX) – Equities researchers at HC Wainwright increased their FY2026 earnings per share (EPS) estimates for Protalix BioTherapeutics in a research report issued on Thursday, March 19th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of $0.26 for the year, up from their prior forecast of $0.20. HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Protalix BioTherapeutics’ current full-year earnings is $0.01 per share. HC Wainwright also issued estimates for Protalix BioTherapeutics’ Q4 2026 earnings at $0.01 EPS, Q1 2027 earnings at $0.01 EPS, Q2 2027 earnings at $0.01 EPS, Q3 2027 earnings at $0.04 EPS and Q4 2027 earnings at $0.08 EPS.

Protalix BioTherapeutics Trading Down 4.0%

NYSE PLX opened at $2.14 on Friday. Protalix BioTherapeutics has a 12 month low of $1.32 and a 12 month high of $3.19. The stock has a 50 day moving average of $2.61 and a 200-day moving average of $2.20. The company has a market cap of $172.10 million, a PE ratio of -16.46 and a beta of -0.26.

Institutional Trading of Protalix BioTherapeutics

A number of large investors have recently added to or reduced their stakes in the company. R Squared Ltd bought a new position in shares of Protalix BioTherapeutics in the 4th quarter valued at about $26,000. Police & Firemen s Retirement System of New Jersey bought a new stake in shares of Protalix BioTherapeutics in the 2nd quarter valued at about $27,000. SG Americas Securities LLC bought a new stake in shares of Protalix BioTherapeutics in the 4th quarter valued at about $31,000. Bank of America Corp DE lifted its stake in Protalix BioTherapeutics by 364,766.7% in the 2nd quarter. Bank of America Corp DE now owns 21,892 shares of the company’s stock valued at $32,000 after purchasing an additional 21,886 shares during the last quarter. Finally, Marshall Wace LLP acquired a new stake in Protalix BioTherapeutics in the 4th quarter valued at about $34,000. Institutional investors and hedge funds own 16.53% of the company’s stock.

About Protalix BioTherapeutics

Protalix BioTherapeutics (NYSE:PLX) is a clinical‐stage biopharmaceutical company focused on the development and manufacturing of recombinant therapeutic proteins through its proprietary ProCellEx® plant cell–based expression system. Headquartered in Carmiel, Israel, with operations in the United States, the company leverages its technology platform to produce complex biologics in a cost‐effective and scalable manner. Protalix’s core expertise lies in engineering plant cells to generate high‐quality therapeutic proteins for rare and specialty diseases.

The company’s first approved commercial product, ELELYSO® (taliglucerase alfa), received regulatory approval from the U.S.